Molecular Subgroup Findings of IMmotion151 in RCC

Brian Rini, MD

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses subgroup findings from the IMmotion151 trial in metastatic renal cell carcinoma. 

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses subgroup findings from the IMmotion151 trial in metastatic renal cell carcinoma (mRCC).

IMmotion151 evaluated the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) compared with sunitinib (Sutent) in patients with mRCC. In an effort to differentiate response by subgroup, Rini says that findings varied according to molecular profile and risk factor.

In the T effector—high subgroup, patients did better with the combination of atezolizumab plus bevacizumab. Rini says that is not surprising, as these patients are known to respond well to immunotherapy. Patients who had gene expression that was angiogenesis-high did better on sunitinib than those with tumors that were angiogenesis-low.